In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. Also in July, Heidelberg Pharma (Wilex) and Advanced Proteome Therapeutics entered into a partnership that will test the combination of Advanced Proteome Therapeutic s proprietary site-specific protein modification technology and Heidelberg Pharma s proprietary ATAC technology in order to generate a cancer therapeutic with enhanced characteristics that can also serve as a prototype for a new generation of antibody-drug conjugates (ADCs). ...In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. Also in July, Heidelberg Pharma (Wilex) and Advanced Proteome Therapeutics entered into a partnership that will test the combination of Advanced Proteome Therapeutic s proprietary site-specific protein modification technology and Heidelberg Pharma s proprietary ATAC technology in order to generate a cancer therapeutic with enhanced characteristics that can also serve as a prototype for a new generation of antibody-drug conjugates (ADCs). As of information reported in June ----, Boehringer Ingelheim and Inventiva are to enter into a new multi-year R&D drug discovery collaboration and licensing agreement, which reflects Boehringer Ingelheim intent to stablish a dominant position in the niche market of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. ...As of information reported in June ----, Boehringer Ingelheim and Inventiva are to enter into a new multi-year R&D drug discovery collaboration and licensing agreement, which reflects Boehringer Ingelheim intent to stablish a dominant position in the niche market of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. In May ----, Iceland-based Alvotech entered into a definitive agreement to acquire Germany-based Baliopharm GmbH, previously a subsidiary of Baliopharm AG, an operation that will provide Alvotech with complementary capabilities in the area of biosimilar development.
...In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. In June ----, the German Federal Supreme Court granted Eli Lilly s appeal in its case against Actavis (Allergan), vacating the prior decision that had denied patent infringement. ...In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. In June ----, the German Federal Supreme Court granted Eli Lilly s appeal in its case against Actavis (Allergan), vacating the prior decision that had denied patent infringement. The case centres on whether Lilly s patent for Alimta (pemetrexed disodium) would be infringed by Actavis proposed generic competitor in Germany. ...The case centres on whether Lilly s patent for Alimta (pemetrexed disodium) would be infringed by Actavis proposed generic competitor in Germany.
...BMI View: Germany s large and expanding pharmaceutical market will continue to generate commercial opportunities for drugmakers over the forecast period. While Germany s ongoing economic rebalancing will continue to support robust domestic consumption indices, including in health sector segments, healthcare spending will also be driven by population growth owing to net migration in the medium term. ...